Cargando…

Clinical spectrum and prognostic value of TP53 mutations in circulating tumor DNA from breast cancer patients in China

BACKGROUND: TP53 mutations are common in breast cancer. There is currently no large‐scale cohort study to investigate the TP53 landscape in breast cancer patients from China. The predictive value of TP53 mutations for the efficacy of human epidermal growth factor receptor 2 (HER2)‐targeted therapy i...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yi, Zongbi, Ma, Fei, Rong, Guohua, Guan, Yanfang, Li, Chunxiao, Xu, Binghe
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2020
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7307233/ https://www.ncbi.nlm.nih.gov/pubmed/32436611 http://dx.doi.org/10.1002/cac2.12032

Ejemplares similares

Mutational characteristics determined using circulating tumor DNA analysis in triple‐negative breast cancer patients with distant metastasis
por: Rong, Guohua, et al.
Publicado: (2020)

DNA damage response as a prognostic indicator in metastatic breast cancer via mutational analysis
por: Rong, Guohua, et al.
Publicado: (2021)

Molecular landscape of TP53 mutations in breast cancer and their utility for predicting the response to HER‐targeted therapy in HER2 amplification‐positive and HER2 mutation‐positive amplification‐negative patients
por: Liu, Binliang, et al.
Publicado: (2022)

Landscape of somatic mutations in different subtypes of advanced breast cancer with circulating tumor DNA analysis
por: Yi, Zongbi, et al.
Publicado: (2017)

TP53 mutations on circulating cell-free DNA
por: Pantel, Klaus
Publicado: (2016)

Prognostic value genotypes and LOH at TP53 codon 72 and TP53 mutations in primary breast cancer
por: Kyndi, M, et al.
Publicado: (2005)

The prognostic value of TP53 mutations in hypopharyngeal squamous cell carcinoma
por: Omura, Go, et al.
Publicado: (2017)

Epithelial-Mesenchymal-Transition-Like Circulating Tumor Cell-Associated White Blood Cell Clusters as a Prognostic Biomarker in HR-Positive/HER2-Negative Metastatic Breast Cancer
por: Guan, Xiuwen, et al.
Publicado: (2021)

Everolimus in hormone receptor-positive metastatic breast cancer: PIK3CA mutation H1047R was a potential efficacy biomarker in a retrospective study
por: Yi, Zongbi, et al.
Publicado: (2019)

Independent prognostic value of somatic TP53 gene mutations in 1794 breast cancer patients
por: Olivier, M, et al.
Publicado: (2005)

The prognostic value of TP53 mutations in oesophageal adenocarcinoma: a systematic review and meta-analysis
por: Fisher, Oliver M, et al.
Publicado: (2017)

The Prognostic Value of TP53 Mutations in Adult Acute Myeloid Leukemia: A Meta-Analysis
por: Qin, Guoxiang, et al.
Publicado: (2022)

Germline TP53 mutational spectrum in French Canadians with breast cancer
por: Arcand, Suzanna L, et al.
Publicado: (2015)

The TP53 website: an integrative resource centre for the TP53 mutation database and TP53 mutant analysis
por: Leroy, Bernard, et al.
Publicado: (2013)

Molecular landscape and efficacy of HER2-targeted therapy in patients with HER2-mutated metastatic breast cancer
por: Yi, Zongbi, et al.
Publicado: (2020)

Prognostic Value of the TP53 Mutation Location in Metastatic Breast Cancer as Detected by Next-Generation Sequencing
por: Bai, Han, et al.
Publicado: (2021)

Prognostic value of baseline genetic features and newly identified TP53 mutations in advanced breast cancer
por: Zhang, Lanxin, et al.
Publicado: (2022)

Prediction of TP53 mutations by p53 immunohistochemistry and their prognostic significance in gastric cancer
por: Hwang, Hye Jung, et al.
Publicado: (2020)

TP53 mutation detected in circulating exosomal DNA is associated with prognosis of patients with hepatocellular carcinoma
por: Li, Yong, et al.
Publicado: (2022)

Analysis of the hormone receptor status of circulating tumor cell subpopulations based on epithelial-mesenchymal transition: a proof-of-principle study on the heterogeneity of circulating tumor cells
por: Guan, Xiuwen, et al.
Publicado: (2016)

TP53 Mutation Spectrum in Smokers and Never Smoking Lung Cancer Patients
por: Halvorsen, Ann R., et al.
Publicado: (2016)

The molecular tumor burden index as a response evaluation criterion in breast cancer
por: Yi, Zongbi, et al.
Publicado: (2021)

The prognostic values of the expression of Vimentin, TP53, and Podoplanin in patients with cervical cancer
por: Lin, Jiaying, et al.
Publicado: (2017)

Molecular characterization of AML‐MRC reveals TP53 mutation as an adverse prognostic factor irrespective of MRC‐defining criteria, TP53 allelic state, or TP53 variant allele frequency
por: Zhao, Davidson, et al.
Publicado: (2022)

Somatic TP53 Mutations Are Detectable in Circulating Tumor DNA from Children with Anaplastic Wilms Tumors()()
por: Treger, Taryn D., et al.
Publicado: (2018)

Mutation spectrum of TP53 gene predicts clinicopathological features and survival of gastric cancer
por: Tahara, Tomomitsu, et al.
Publicado: (2016)

Longitudinal HER2 amplification tracked in circulating tumor DNA for therapeutic effect monitoring and prognostic evaluation in patients with breast cancer
por: Guan, Xiuwen, et al.
Publicado: (2019)

Prognostic value of KRAS/TP53/PIK3CA in non-small cell lung cancer
por: Zhao, Jiayi, et al.
Publicado: (2019)

Studies of TP53 haplotypes in relation to LOH and TP53 mutations in breast cancer patients
por: Langerød, A, et al.
Publicado: (2000)

Safety and efficacy of sirolimus combined with endocrine therapy in patients with advanced hormone receptor-positive breast cancer and the exploration of biomarkers
por: Yi, Zongbi, et al.
Publicado: (2020)

Significant Prognostic Features and Patterns of Somatic TP53 Mutations in Human Cancers
por: Zhang, Wensheng, et al.
Publicado: (2017)

Prognostic Value of TP53 Mutation for Transcatheter Arterial Chemoembolization Failure/Refractoriness in HBV-Related Advanced Hepatocellular Carcinoma
por: Xue, Miao, et al.
Publicado: (2020)

Impact of TP53 mutations in breast cancer: Clinicopathological features and prognosisImpact of TP53 mutations in breast CA
por: Li, Xuerui, et al.
Publicado: (2020)

TP53-Mutated Circulating Tumor DNA for Disease Monitoring in Lymphoma Patients after CAR T Cell Therapy
por: Chen, Liting, et al.
Publicado: (2021)

Prognostic value of LAMP3 and TP53 overexpression in benign and malignant gastrointestinal tissues
por: Sun, Rongwei, et al.
Publicado: (2014)

TP53 Combined Phenotype Score Is Associated with the Clinical Outcome of TP53-Mutated Myelodysplastic Syndromes
por: Yabe, Mariko, et al.
Publicado: (2021)

TP53_PROF: a machine learning model to predict impact of missense mutations in TP53
por: Ben-Cohen, Gil, et al.
Publicado: (2022)

KRAS and TP53 Mutations in Colorectal Carcinoma
por: Al-Kuraya, Khawla S.
Publicado: (2009)

Immunometabolism characteristics and a potential prognostic risk model associated with TP53 mutations in breast cancer
por: Jiang, Mengping, et al.
Publicado: (2022)

Somatic Mutations of TP53 and Prognostic Factors for Primary Operable Breast Cancer: Correspondence
por: Sookaromdee, Pathum, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_9qjbu6hfvbjjmvhvm2sg59bip4